S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                  512--A
 
                        2023-2024 Regular Sessions
 
                           I N  A S S E M B L Y
 
                              January 9, 2023
                                ___________
 
 Introduced  by M. of A. L. ROSENTHAL, SIMON, GALLAGHER, GLICK, SILLITTI,
   SHIMSKY, REYES, CRUZ, LEVENBERG, TAYLOR, RAGA,  DE LOS SANTOS,  WALKER
   --  read  once  and  referred  to the Committee on Health -- committee
   discharged, bill amended, ordered reprinted as amended and recommitted
   to said committee

 AN ACT to amend the public health law, in relation to the creation of  a
   research program to determine the risks posed from potential toxins in
   menstrual  products;  and  providing for the repeal of such provisions
   upon expiration thereof
 
   THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section  1.  Short  title. This act shall be known and may be cited as
 "the menstrual product safety and research act".
   § 2. Title 6 of article 2 of the public health law, as added by  chap-
 ter  342  of the laws of 2014, is amended by adding a new section 269 to
 read as follows:
   § 269. MENSTRUAL PRODUCT SAFETY AND RESEARCH. 1. FOR PURPOSES OF  THIS
 SECTION,  THE  TERM  "MENSTRUAL  PRODUCTS"  MEANS TAMPONS, PADS, LINERS,
 CUPS, SPONGES, DOUCHES, WIPES, SPRAYS,  AND  SIMILAR  PRODUCTS  USED  IN
 CONJUNCTION   WITH   RESPECT  TO  MENSTRUATION  OR  OTHER  GENITAL-TRACT
 SECRETIONS.
   2. THE COMMISSIONER SHALL  PROVIDE  FOR  THE  CONDUCT  OR  SUPPORT  OF
 RESEARCH BY THE DEPARTMENT TO DETERMINE THE EXTENT TO WHICH THE PRESENCE
 OF  DIOXINS, SYNTHETIC FIBERS, CHLORINE, AND OTHER COMPONENTS (INCLUDING
 CONTAMINANTS AND SUBSTANCES USED AS  FRAGRANCES,  COLORANTS,  DYES,  AND
 PRESERVATIVES) IN MENSTRUAL PRODUCTS:
   (A) POSES ANY RISKS TO THE HEALTH OF INDIVIDUALS WHO USE THE PRODUCTS,
 INCLUDING RISKS RELATING TO CERVICAL CANCER, ENDOMETRIOSIS, INFERTILITY,
 OVARIAN  CANCER,  BREAST  CANCER,  IMMUNE  SYSTEM  DEFICIENCIES,  PELVIC
 INFLAMMATORY DISEASE, TOXIC SHOCK  SYNDROME,  AND  BACTERIAL  AND  YEAST
 INFECTIONS; AND
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
                                                            LBD00712-02-3
              

 A. 512--A                           2
 
   (B) POSES ANY RISKS TO THE HEALTH OF BIOLOGICAL CHILDREN BORN TO INDI-
 VIDUALS  WHO  USED  SUCH  PRODUCTS  DURING  OR  BEFORE  THE  PREGNANCIES
 INVOLVED, INCLUDING RISKS RELATING TO FETAL AND CHILDHOOD DEVELOPMENT.
   3.  RESEARCH  UNDER  SUBDIVISION  TWO  OF  THIS  SECTION SHALL INCLUDE
 RESEARCH TO CONFIRM THE DATA ON  MENSTRUAL  PRODUCTS  SUBMITTED  TO  THE
 UNITED  STATES  FOOD  AND  DRUG  ADMINISTRATION BY MANUFACTURERS OF SUCH
 PRODUCTS.
   4. SUCH RESEARCH PROJECTS SHALL BE COMPLETED WITHIN FOUR YEARS OF  THE
 EFFECTIVE DATE OF THIS SECTION.
   5.  WITHIN  ONE  YEAR  OF THE COMPLETION OF SUCH RESEARCH, ANY CONCLU-
 SIONS, RECOMMENDATIONS AND PROPOSALS FOR IMPLEMENTING  SUCH  RECOMMENDA-
 TIONS  SHALL  BE TRANSMITTED TO THE GOVERNOR, THE TEMPORARY PRESIDENT OF
 THE SENATE, THE SPEAKER OF THE ASSEMBLY, THE CHAIR OF THE SENATE  HEALTH
 COMMITTEE,  AND  THE  CHAIR  OF THE ASSEMBLY HEALTH COMMITTEE, AND SHALL
 ALSO BE MADE AVAILABLE TO THE PUBLIC.
   § 3. This act shall take effect on the ninetieth day  after  it  shall
 have  become  a  law  and shall expire and be deemed repealed five years
 after such date.